Zoetis Inc. (LON:0M3Q)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 23.36B -50.7% |
| Revenue (ttm) | 7.18B +1.6% |
| Net Income | 1.99B +1.8% |
| EPS | 4.62 +6.2% |
| Shares Out | n/a |
| PE Ratio | 11.75 |
| Forward PE | 12.27 |
| Dividend | 1.60 (2.84%) |
| Ex-Dividend Date | Oct 30, 2026 |
| Volume | 3,010 |
| Open | 72.67 |
| Previous Close | 73.58 |
| Day's Range | 71.81 - 74.64 |
| 52-Week Range | 68.58 - 148.23 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis Declares Fourth Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will ...
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 2,293 puts trading, or 1.3x expected. Most active are Mar-27 50 puts and Mar-27 65 puts, with total volume in those strikes near…
Zoetis announces peer-review publication on Simparica Trio
New peer-reviewed findings published in the journal Parasites & Vectors show that Zoetis (ZTS)’ Simparica Trio protected more dogs from adult heartworm infection than NexGard Plus in a controlled, hea...
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows t...
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 2,600 puts trading, or 1.4x expected. Most active are Oct-26 65 puts and Nov-26 65 puts, with total volume in those strikes near…
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristi...
Zoetis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership emphasized value creation through innovation and targeted pricing amid a declining pet care market and rising competition. Strong livestock growth and a robust product pipeline, including CKD and oncology, support long-term optimism. Market stabilization and recovery in pet care are key to resuming sustainable growth.
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Ope...
Zoetis price target lowered to $94 from $104 at TD Cowen
TD Cowen analyst Steve Scala lowered the firm’s price target on Zoetis (ZTS) to $94 from $104 and keeps a Buy rating on the shares. The firm reduced their near-term…
Zoetis price target lowered to $80 from $85 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Zoetis (ZTS) to $80 from $85 and keeps a Hold rating on the shares.
FDA issues Zoetis Emergency Use Authorization for Simparica TRIO for screwworm
The U.S. Food and Drug Administration issued an Emergency Use Authorization for Simparica TRIO for the treatment of New World screwworm infestations in dogs and puppies. “Currently, most dogs in…
Zoetis confirms FDA Emergency Use Authorization for Simparica Trio
Zoetis (ZTS) announced that Simparica Trio has received Emergency Use Authorization from the U.S. FDA for the treatment of infestations caused by New World screwworm larvae in dogs and puppies.
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA...
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
Zoetis price target lowered to $96 from $112 at Citi
Citi lowered the firm’s price target on Zoetis (ZTS) to $96 from $112 and keeps a Buy rating on the shares. The firm updated its ratings and targets in the…
Zoetis price target lowered to $80 from $90 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Zoetis (ZTS) to $80 from $90 and keeps a Neutral rating on the shares following quarterly results. The firm…
Zoetis price target lowered to $85 from $99 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $85 from $99 and keeps an Overweight rating on the shares.
Zoetis price target lowered to $80 from $85 at UBS
UBS analyst Andrea Alfonso lowered the firm’s price target on Zoetis (ZTS) to $80 from $85 and keeps a Neutral rating on the shares.
Zoetis downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Zoetis (ZTS) to Market Perform from Outperform.
William Blair downgrades Zoetis, sees ‘too much uncertainty’
As previously reported, William Blair downgraded Zoetis (ZTS) to Market Perform from Outperform after Q2 results included worse-than-expected derm declines, continued Trio share loss, and continued de...
Zoetis Earnings Call Transcript: Q2 2026
Q2 2026 saw flat revenue and a 2% decline in adjusted net income, with U.S. companion animal under pressure from declining clinic visits and heightened competition, while international and livestock segments showed growth. Full-year guidance was revised downward, reflecting persistent headwinds and increased promotional activity.
Zoetis Slides: Q2 2026
Zoetis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Zoetis Earnings release: Q2 2026
Zoetis released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zoetis Quarterly report: Q2 2026
Zoetis has published its Q2 2026 quarterly earnings report on August 6, 2026.
Zoetis cuts annual forecasts as pet healthcare demand slows
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competiti...